Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Atrium Therapeutics, Inc. - Common Stock
(NQ:
RNA
)
14.82
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atrium Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
↗
May 23, 2024
Discover three top Nasdaq stocks to buy. Learn about these investment opportunities and why they’re worth your attention.
Via
InvestorPlace
RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024
↗
May 09, 2024
RNA stock results show that Avidity Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Navigating 7 Analyst Ratings For Avidity Biosciences
↗
May 03, 2024
Via
Benzinga
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
↗
April 18, 2024
Via
Benzinga
Topics
ETFs
Where Avidity Biosciences Stands With Analysts
↗
April 11, 2024
Via
Benzinga
This Demand Zone In S&P 500 Needs To Hold
↗
April 03, 2024
Find out the demand zone that the S&P 500 needs to hold to avoid a meaningful pullback.
Via
Talk Markets
Topics
Stocks
A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
↗
March 05, 2024
Via
Benzinga
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
↗
March 14, 2024
Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising treatment for Myotonic dystrophy type 1. With strong management, proven...
Via
Benzinga
American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
March 05, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Avidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Disease
↗
March 04, 2024
New AOC 1001 data from Avidity Biosciences show reversal of disease progression in DM1 patients, using key endpoints in Phase 3 HARBOR trial.
Via
Benzinga
Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy
↗
March 04, 2024
The company is working on a treatment for myotonic dystrophy type 1, a form of muscular dystrophy.
Via
Investor's Business Daily
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
↗
March 04, 2024
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday.
Via
Benzinga
Topics
Stocks
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
March 04, 2024
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its...
Via
Benzinga
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
↗
February 29, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday.
Via
Benzinga
Topics
Stocks
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
February 29, 2024
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
Via
Benzinga
Top 3 Health Care Stocks You May Want To Dump In Q1
↗
February 29, 2024
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
↗
February 29, 2024
Tech stocks drive pre-market surge, Fed inflation data fails to disrupt rate cut expectations. Futures up for Nasdaq, S&P 500, and small caps.
Via
Benzinga
Topics
Economy
Stocks
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
February 29, 2024
Via
Benzinga
3 Highly Rated Biotech Stocks to Buy for 300% Gains
↗
February 26, 2024
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.
Via
InvestorPlace
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
November 28, 2023
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
Via
Benzinga
FCEL Stock Alert: FuelCell Energy Announces AI Deal With IBM
↗
November 28, 2023
FuelCell Energy stock is climbing higher on Tuesday as investors in FCEL celebrate the company signing a deal with IBM!
Via
InvestorPlace
Topics
Artificial Intelligence
Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts
↗
November 28, 2023
Novocure layoffs are coming for 13% of the company's workers as it seeks to reduce its headcount by 200 people to reduce costs.
Via
InvestorPlace
Topics
Workforce
Lion Electric Layoffs 2023: What to Know About the Latest LEV Job Cuts
↗
November 28, 2023
Lion Electric layoffs are coming for 150 of the electric bus company's employees as it seeks to reduce its headcount by 10%.
Via
InvestorPlace
Topics
Electric Vehicles
Workforce
Why Is Avidity Biosciences (RNA) Stock Up 15% Today?
↗
November 28, 2023
RNA stock is jumping over 15% in early trading after Avidity announced its expanded alliance with Bristol-Myers Squibb.
Via
InvestorPlace
PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday
↗
November 28, 2023
U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Tuesday.
Via
Benzinga
Topics
Stocks
US Stocks Mixed; House Prices Rise In September
↗
November 28, 2023
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 10 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.04% to 35,345.85 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?
↗
November 28, 2023
Avidity Biosciences Inc (NASDAQ: RNA) announced a global licensing and research collaboration with Bristol Myers Squibb & Co (NYSE: BMY) focused on discovering, developing, and commercializing multiple...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
November 28, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
November 28, 2023
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today!
Via
InvestorPlace
Avidity Biosciences' Muscle Disease Candidate Shows Improvement in Multiple Additional Functional Endpoints, Safety
↗
October 09, 2023
Avidity Biosciences Inc (NASDAQ: RNA) announced new AOC 1001 data demonstrating improvement in multiple additional functional endpoints and favorable long-term safety and tolerability for myoton
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.